Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

Plinabulin Improves Survival in Non–Small-Cell Lung Cancer

TOP - May 2017, Vol 10, No 2 - Lung Cancer

Orlando, FL—When added to treatment with docetaxel, the investigational drug plinabulin improved overall survival by 4.7 months in patients with advanced non–small-cell lung cancer with measurable lesions. Data from the phase 2 randomized trial also demonstrated durable responses, with median duration of response exceeding 1 year versus <2 months with docetaxel alone.

“We saw very encouraging activity for plinabulin in patients with measurable lung disease. In addition to durable responses, there was an extended survival benefit of approximately 5 months in these patients,” said Alain C. Mita, MD, Co-Director, Experimental Therapeutics, Cedars-Sinai Medical Center, Los Angeles, CA.

As Dr Mita reported at the 2017 Society for Immunotherapy of Cancer Clinical Immuno-Oncology Symposium, plinabulin is a small molecule with tumor-inhibiting and immune-enhancing effects. For this phase 2 trial, investigators enrolled 163 patients with stage IIIB and stage IV non–small-cell lung cancer who had received 1 or 2 previous treatments. Patients were randomly assigned to treatment with plinabulin plus docetaxel or docetaxel alone. Docetaxel was dosed at 75 mg/m2 across all arms on day 1 of a 21-day cycle, and plinabulin (20 or 30 mg/m2) was administered on days 1 and 8.

Although the combination of plina­bulin plus docetaxel yielded only a modest benefit in the overall study population, in the subset of patients with measurable lesions, median duration of response improved from 1.5 months with docetaxel alone to 12.7 months with the addition of plinabulin. Furthermore, among the 76 patients with measurable disease, median overall survival increased to 11.3 months, compared with 6.7 months with docetaxel alone. Because of a small population size, the 4.6-month improvement in overall survival did not meet significance (P = .26), but the nearly 1-year improvement in duration of response was significant (P <.05), Dr Mita reported.

The addition of plinabulin appeared to exacerbate diarrhea, nausea, vomiting, headache, dizziness, and hypertension; however, the vast majority of these adverse events were “mild, transient, and responded to dose reduction to 20 mg/m2,” said Dr Mita.

Based on these findings, the global phase 3 DUBLIN-3 trial is underway to evaluate second- or third-line treatment with plinabulin and docetaxel in patients with ≥1 measurable lung lesions. At the same time, other non–small-cell lung cancer trials are examining plinabulin’s “potent immune-enhancing effects.”

According to Dr Mita, preclinical research in colon and breast tumor models has suggested that plinabulin works in synergy with other immunotherapies to slow tumor growth by operating through mechanisms distinct from PD-1/PD-L1 inhibition. Two investigator-initiated phase 1/2 trials of plinabulin in combination with nivolumab will explore this interaction.

Discussant Heather L. McArthur, MD, MPH, Medical Director, Breast Oncology, Cedars-Sinai Medical Center, called the dramatic increase in overall survival and duration of response “provocative.” Nevertheless, said Dr McArthur, given plinabulin’s complicated mechanism of action, there is still a lot to learn about the drug.

“It will be important to tease apart the influence of bona fide antitumor effects of the agent from its neutrophil-protecting effects, as the latter may not be of much help when plinabulin is combined with noncytotoxic immunotherapies,” she concluded.

Related Items
Antibody–Drug Conjugate Shows Promising Activity in Patients with Advanced or Metastatic EGFR Mutation–Positive NSCLC
Patricia Stewart
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in Lung Cancer
Amivantamab plus Lazertinib Combo Improves Response in Osimertinib-Resistant EGFR-Positive NSCLC
Patricia Stewart
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in Lung Cancer
Sotorasib Shows Encouraging Activity in Patients with NSCLC and KRAS p.G12C Mutation
Patricia Stewart
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Lung Cancer
Neoadjuvant Nivolumab plus Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Resectable NSCLC
Patricia Stewart
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Lung Cancer
Educating NSCLC Patients on Adverse Event Management
Kammi Fox-Kay, MSN, RN, AOCNS, ONN-CG(T), Cathy Simmons, RN, BSN, ONN-CG(T), Lauren Welch, MSN, NP-C, AOCNP
Videos published on July 8, 2021 in Interview with the Innovators, Lung Cancer, Adverse Events
Addressing Lung Cancer Screening Disparities in LGBT Populations
William Ackerman
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in Lung Cancer
Analysis Identifies EGFR as Most Common Mutation in Women with Lung Cancer and No Smoking History
William Ackerman
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in Lung Cancer
Cemiplimab Potential New Treatment Option for Patients with Advanced NSCLC and PD-L1 ≥50%
Patricia Stewart
TOP - January 2021 Vol 14, No 1 published on February 9, 2021 in Lung Cancer
“Astonishing Results” Seen with First-Line Lorlatinib for the Treatment of ALK-Positive NSCLC
Patricia Stewart
TOP - January 2021 Vol 14, No 1 published on February 9, 2021 in Lung Cancer
Patients with BRAF V600E–Mutant NSCLC Show Improved Overall Survival with Dabrafenib + Trametinib Combination
2020 Year in Review - Non–Small-Cell Lung Cancer published on January 29, 2021 in Lung Cancer
Last modified: July 22, 2021